Cardioprotection for patients receiving anthracycline-based therapy for nonmetastatic breast cancer
Prof. Icro Meattini
Several studies have evaluated cardioprotective strategies to prevent myocardial dysfunction in patients who are receiving cardiotoxic therapies. There is no consensus on the optimal approach. The Italian multicenter phase 3 SAFE trial found that cardioprotection with ramipril and/or bisoprolol was effective and well tolerated by patients receiving anthracycline-based chemotherapy for nonmetastatic breast cancer.
